Anzeige
Mehr »
Login
Mittwoch, 19.05.2021 Börsentäglich über 12.000 News von 658 internationalen Medien
Im Fokus: Unglaubliche Steigerung der Goldproduktion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J1BH ISIN: US8036071004 Ticker-Symbol: AB3A 
Tradegate
18.05.21
21:49 Uhr
67,16 Euro
+5,42
+8,78 %
1-Jahres-Chart
SAREPTA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SAREPTA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
66,2067,5618.05.
66,3066,9618.05.

Aktuelle News zur SAREPTA THERAPEUTICS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiSarepta Therapeutics, Inc. (SRPT) Presents at RBC Capital Markets Global Healthcare Broker Conference Call - (Transcript)3
DiSarepta shares rally on early DMD data that also reveals 2 serious, 79 mild side effects7
DiSarepta's stock is up 11% on positive data from clinical trial for Duchenne treatment4
SAREPTA THERAPEUTICS Aktie jetzt für 0€ handeln
DiSarepta keeps momentum as DMD data draw positive views from analysts2
DiWhy Sarepta Might Have Just Reversed Its Fortunes In Gene Therapy3
DiSarepta touts clean data for commercial grade Duchenne gene therapy, clearing key hurdle to PhIII2
DiSarepta Higher After Progress With Muscular Dystrophy Drug Trial3
DiStock Alert: Sarepta Therapeutics Up 9%1
DiSarepta's Gene Therapy For Treatment Of Duchenne Muscular Dystrophy Shows Robust Expression190SOUTH SAN FRANCISCO (dpa-AFX) - Sarepta Therapeutics Inc. (SRPT) said that its investigational gene therapy for the treatment of duchenne muscular dystrophy, SRP-9001, demonstrated robust expression...
► Artikel lesen
DiSarepta posts positive data from SRP-9001 DMD study14
DiSarepta Therapeutics, Inc. - 8-K, Current Report2
DiSarepta Therapeutics, Inc.: Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates ...6
MoSarepta Therapeutics, Inc.: Sarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational ...10
06.05.Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates5
06.05.Why Sarepta's Q1 Results Won't Spark a Rebound for the Beaten-Down Biotech8
06.05.Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q1 2021 Results - Earnings Call Transcript5
05.05.Sarepta Therapeutics Q1 adjusted earnings Beat Estimates254WASHINGTON (dpa-AFX) - Below are the earnings highlights for Sarepta Therapeutics (SRPT):-Earnings: -$167.25 million in Q1 vs. -$17.49 million in the same period last year. -EPS: -$2.10 in...
► Artikel lesen
05.05.Sarepta Therapeutics, Inc.: Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments7
05.05.Sarepta Therapeutics, Inc. - 10-Q, Quaterly Report-
04.05.Sarepta Therapeutics, Inc.: Sarepta Therapeutics to Present at Upcoming Investor Conferences3
Seite:  Weiter >>
121 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
19,5,25